NEW YORK, July 22, 2004 (GenomeWeb News) - Sequenom and the National Human Genome Research Institute announced today that they will perform allele-specific gene expression of genes that confer susceptibility to type 2 diabetes, building upon a previous research collaboration between the partners.
Under the three-year Cooperative Research and Development Agreement, researchers will use Sequenom's MassArray Quantitate Gene Expression in conducting the study.
Sequenom and the NHGRI had previously collaborated on analyzing DNA for single nucleotide polymorphisms that correlate to type 2 diabetes. According to a release issued by San Diego-based Sequenom, the work builds upon research conducted by the NHGRI for the Finland-US Investigation of non-insulin dependent diabetes mellitus (FUSION) project.
In April, Sequenom announced that its MassArray system had been used in the identification of a novel association between the HNF4A gene and type 2 diabetes. The results of that study, entitled "Genetic Variation Near the Hepatocyte Nuclear Factor-4A Gene Predicts Susceptibility to Type 2 Diabetes," were published in the April 2004 issue of Diabetes. It was conducted by a team from the